UNSPSC 51283305: Levofuraltadone

This classification denotes an antimicrobial solution, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier V6H66N6UDU. European Medicines Agency schedules Levofuraltadone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08472MIG. Levofuraltadone generally arises in the molecular formula C13H16N4O6.

The term LEVOFURALTADONE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, volume 21 no. 12 1967, list 7.) LEVOFURALTADONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: O1C(CN2CCOCC2)CN(/N=C/C2OC([N](=O)O)CC2)C1=O.

UNSPSC 51283305 Levofuraltadone is a Commodity code that does not reflect the pharmaceutical products state and local governments are actually purchasing under it. The most recent opportunities solicited under this code show no levofuraltadone procurement; instead, state and local buyers are purchasing naloxone, doxycycline hyclate, ciprofloxacin hydrochloride, and safe drug deactivation systems through pharmaceutical warehouse and emergency-response procurement channels. These purchases support community health and emergency-response initiatives rather than the specific pharmaceutical named in the code. Issuing bodies using this code include state health departments and county health and emergency services authorities pursuing competitive procurement vehicles such as ITBs and IFBs for pharmaceutical supply contracts often leveraging regional cooperative purchasing consortia.

Recent activity appears in Florida and Illinois. Seminole County, Florida issued an IFB (Number IFB60459723LAS) in June 2026 to procure 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, response deadline July 26, 2023. The Illinois Department of Public Health awarded a piggyback pharmaceutical warehouse contract through the MMCAP Infuse consortium to Chartwell Rx LLC in August 2026 for doxycycline hyclate 100mg tablets and ciprofloxacin hydrochloride 500mg tablets valued at $2,999,999.11 over the contract life including renewals, with an initial 12-month term and options for years 2 and 3. The code shows minimal activity with a clear mismatch between its nominal scope and actual procurement demand; vendors should verify accurate UNSPSC coding before responding to opportunities tagged under this number.